Emerging targeted agents in metastatic breast cancer - PubMed (original) (raw)
Review
. 2013 Apr;10(4):191-210.
doi: 10.1038/nrclinonc.2013.29. Epub 2013 Mar 5.
Affiliations
- PMID: 23459626
- DOI: 10.1038/nrclinonc.2013.29
Review
Emerging targeted agents in metastatic breast cancer
Dimitrios Zardavas et al. Nat Rev Clin Oncol. 2013 Apr.
Abstract
Extensive preclinical experimentation has conceptually changed the way we perceive breast cancer, with the wide spectrum of genomic alterations governing its malignant progression now being recognized. Functional genomics has helped us identify important genetic defects that can be pharmaceutically targeted in the setting of metastatic disease. Rationally chosen combination regimens are now under clinical investigation. Recent data underline the functional importance of the tumour-associated stroma, with several candidate molecular targets now emerging. Data elucidating a cellular hierarchy within the breast cancer cellular compartment support the existence of a therapy-resistant subpopulation of breast cancer stem cells. Identification of the developmental pathways that dictate their malignant phenotype and use of high-throughput screening techniques are leading to new therapeutic avenues. In this Review, we present the biological rationale for the clinical development of more than 15 different classes of targeted agents in breast cancer, along with evidence supporting rational combinations. However, metastatic breast cancer resembles a Darwinian evolutionary system, with 'driver' mutations and epigenetic changes determining clonal selection according to branching trajectories. This evolution is reflected in the molecular heterogeneity of the disease and poses severe impediments to the successful clinical development of emerging targeted agents.
Similar articles
- Putting the brakes on breast cancer: therapeutic opportunities to bring cancer stem cells and the tumor microenvironment to a screeching halt.
Vargo-Gogola T. Vargo-Gogola T. Curr Drug Targets. 2010 Sep;11(9):1041-2. doi: 10.2174/138945010792006834. Curr Drug Targets. 2010. PMID: 20545615 No abstract available. - Emerging therapeutic targets in metastatic progression: A focus on breast cancer.
Li Z, Kang Y. Li Z, et al. Pharmacol Ther. 2016 May;161:79-96. doi: 10.1016/j.pharmthera.2016.03.003. Epub 2016 Mar 19. Pharmacol Ther. 2016. PMID: 27000769 Free PMC article. Review. - Cancer stem cells in solid and liquid tissues of breast cancer patients: characterization and therapeutic perspectives.
Chiotaki R, Polioudaki H, Theodoropoulos PA. Chiotaki R, et al. Curr Cancer Drug Targets. 2015;15(3):256-69. doi: 10.2174/1568009615666150211102503. Curr Cancer Drug Targets. 2015. PMID: 25669721 Review. - Targeting Breast Cancer Stem Cells: A Methodological Perspective.
Velasco-Velázquez MA, Velázquez-Quesada I, Vásquez-Bochm LX, Pérez-Tapia SM. Velasco-Velázquez MA, et al. Curr Stem Cell Res Ther. 2019;14(5):389-397. doi: 10.2174/1574888X13666180821155701. Curr Stem Cell Res Ther. 2019. PMID: 30147014 Review. - Notch Signaling in Breast Cancer: A Role in Drug Resistance.
BeLow M, Osipo C. BeLow M, et al. Cells. 2020 Sep 29;9(10):2204. doi: 10.3390/cells9102204. Cells. 2020. PMID: 33003540 Free PMC article. Review.
Cited by
- Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
Gupta GK, Collier AL, Lee D, Hoefer RA, Zheleva V, Siewertsz van Reesema LL, Tang-Tan AM, Guye ML, Chang DZ, Winston JS, Samli B, Jansen RJ, Petricoin EF, Goetz MP, Bear HD, Tang AH. Gupta GK, et al. Cancers (Basel). 2020 Aug 24;12(9):2392. doi: 10.3390/cancers12092392. Cancers (Basel). 2020. PMID: 32846967 Free PMC article. Review. - Luminal breast cancer: from biology to treatment.
Ignatiadis M, Sotiriou C. Ignatiadis M, et al. Nat Rev Clin Oncol. 2013 Sep;10(9):494-506. doi: 10.1038/nrclinonc.2013.124. Epub 2013 Jul 23. Nat Rev Clin Oncol. 2013. PMID: 23881035 Review. - Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?
Schneeweiss A, Ruckhäberle E, Huober J. Schneeweiss A, et al. Geburtshilfe Frauenheilkd. 2015 Jun;75(6):574-583. doi: 10.1055/s-0035-1546150. Geburtshilfe Frauenheilkd. 2015. PMID: 26166838 Free PMC article. Review. - Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer.
Long Q, Ma AH, Zhang H, Cao Z, Xia R, Lin TY, Sonpavde GP, de Vere White R, Guo J, Pan CX. Long Q, et al. Cancer Immunol Immunother. 2020 Nov;69(11):2305-2317. doi: 10.1007/s00262-020-02609-5. Epub 2020 Jun 6. Cancer Immunol Immunother. 2020. PMID: 32506263 Free PMC article. - Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer.
Kimura M, Hanamura T, Tsuboi K, Kaneko Y, Yamaguchi Y, Niwa T, Narui K, Endo I, Hayashi SI. Kimura M, et al. Oncotarget. 2018 Apr 20;9(30):21468-21477. doi: 10.18632/oncotarget.25133. eCollection 2018 Apr 20. Oncotarget. 2018. PMID: 29765553 Free PMC article.
References
- Mol Cancer Ther. 2012 Apr;11(4):973-83 - PubMed
- Nat Rev Drug Discov. 2009 Aug;8(8):627-44 - PubMed
- Cancer Res. 2012 Jun 1;72(11):2768-79 - PubMed
- PLoS One. 2011 Jan 13;6(1):e15313 - PubMed
- Nature. 2012 May 16;486(7403):400-4 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical